Sustained released intravitreal implants(University of Kentucky)

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameSustained released intravitreal implants(University of Kentucky)
Drug Alias NameKamuvudine-8(University of Kentucky)SOM-401K8
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReverse transcriptase inhibitorsNACHT, LRR and PYD domains-containing protein 3 inhibitorsInflammasomes inhibitors
TargetsReverse transcriptaseNACHT, LRR and PYD domains-containing protein 3Inflammasomes
Therapy Area/IndicationsDiabetic macular oedemaGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of KentuckyInflammasome Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInflammasome Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaGeographic AtrophyMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A